Reverse iontophoretic monitoring in premature neonates: feasibility and potential.

Premature neonates represent a fragile patient population, often subjected to intensive clinical care and multiple drug therapy, which must be monitored carefully and continuously. The difficult and painful nature of repetitive blood sampling, particularly in this population, has provided considerable impetus for the development of noninvasive methods for monitoring blood analytes. Reverse iontophoresis, a relatively new technology already used for the transdermal monitoring of blood glucose levels in adults, may be particularly well-suited to exploit the unique properties of preterm neonatal skin. The underdevelopment of the premature infant's epidermis, and more specifically the stratum corneum (SC), results in an increased permeability to molecular transport. In this study, we have investigated the feasibility of reverse iontophoretic monitoring of two model drugs, caffeine and theophylline, which are often administered to premature neonates. To this purpose, tape-stripped porcine skin in vitro, which has been previously demonstrated to be an excellent model for premature neonatal skin, was employed. Reverse iontophoresis across intact membranes enabled a quantifiable extraction of both drugs predominantly at the cathode compartment. The mechanism of extraction of these essentially neutral drugs (caffeine and theophylline being uncharged at pH 7.4) was electroosmosis. However, when the SC was removed by progressive tape-stripping, the amounts of drugs extracted by reverse iontophoresis were equivalent to those obtained by passive diffusion. In these circumstances, therefore, the benefit and usefulness of the applied electric field had been lost. In summary, the absence of an at least partially functional skin barrier obviates, in the case of neutral molecules, the control (and directional transport) offered by iontophoresis; in contrast, for ionized species, where the principal iontophoretic transport mechanism is electromigration, the approach should be valid.

[1]  R. Guy,et al.  A New System for In Vitro Studies of Iontophoresis , 1988, Pharmaceutical Research.

[2]  J. Miners,et al.  The simultaneous determination of theophylline, theobromine and caffeine in plasma by high performance liquid chromatography. , 1980, Clinical biochemistry.

[3]  W. Hop,et al.  Use of Saliva in Therapeutic Drug Monitoring of Caffeine in Preterm Infants , 2001, Therapeutic drug monitoring.

[4]  A S Gross Best practice in therapeutic drug monitoring. , 1998, British journal of clinical pharmacology.

[5]  J. Hadgraft,et al.  The back diffusion of glucose across human skin in vitro , 1999 .

[6]  K. Sugibayashi,et al.  Non-invasive sampling of lactic acid ions by iontophoresis using chloride ion in the body as an internal standard. , 1993, Journal of Pharmaceutical and Biomedical Analysis.

[7]  J. McCormack,et al.  Drug Concentration Monitoring , 1993, Clinical pharmacokinetics.

[8]  J. Blumer,et al.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). , 1988, Clinical pharmacokinetics.

[9]  G. Koren Therapeutic drug monitoring principles in the neonate , 1997 .

[10]  V. Langer Minimal handling protocol for the intensive care nursery. , 1990, Neonatal network : NN.

[11]  P. Gal,et al.  Usefulness of theophylline saliva levels in neonates. , 1983, Therapeutic drug monitoring.

[12]  P. Steer,et al.  Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. , 1996, Therapeutic drug monitoring.

[13]  Richard H. Guy,et al.  Noninvasive Sampling of Biological Fluids by Iontophoresis , 1989, Pharmaceutical Research.

[14]  L. Jovanovic,et al.  Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. , 1999, JAMA.

[15]  R. Guy,et al.  Reverse iontophoresis — parameters determining electro-osmotic flow. II. Electrode chamber formulation , 1996 .

[16]  R O Potts,et al.  Detection of hypoglycemia with the GlucoWatch biographer. , 2001, Diabetes care.

[17]  R. Guy,et al.  Noninvasive sampling of phenylalanine by reverse iontophoresis. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[18]  R. Guy,et al.  Characterization of Convective Solvent Flow During Iontophoresis , 1994, Pharmaceutical Research.

[19]  Susan Budavari,et al.  The Merck index , 1998 .

[20]  J. Blumer,et al.  Principles of Drug Biodisposition in the Neonate , 2012 .

[21]  G. Budreau,et al.  Clinical indicators of infant irritability. , 1991, Neonatal network : NN.

[22]  R. Guy,et al.  Reverse iontophoresis — Parameters determining electroosmotic flow: I. pH and ionic strength , 1996 .

[23]  R H Guy,et al.  Characterization of the iontophoretic permselectivity properties of human and pig skin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[24]  R H Guy,et al.  Transdermal therapy and diagnosis by iontophoresis. , 1997, Trends in biotechnology.

[25]  N. Rutter,et al.  Transdermal delivery and the premature neonate. , 1994, Critical reviews in therapeutic drug carrier systems.

[26]  G. Merenstein,et al.  Transcutaneous theophylline collection in preterm infants , 1990, Clinical pharmacology and therapeutics.